Evonik increases supply of critical lipids for the Pfizer-BioNTech COVID-19 vaccine

Evonik is strengthening its strategic partnership with BioNTech in order to establish additional lipid production in Germany for use with mRNA-based COVID-19 vaccines.

Commercial lipid quantities are to be produced at Evonik’s Hanau and Dossenheim sites in Germany as early as the second half of 2021 as part of a strategic partnership with vaccine manufacturer BioNTech. Evonik is making an important contribution to increasing the supply security of the Pfizer-BioNTech COVID-19 vaccine.

Evonik lipid
In mRNA-based vaccines, the mRNA is enclosed in a lipid nanoparticle (LNP) that is comprised of specific lipids

Critical lipids

“The pandemic requires decisive action,” says Christian Kullmann, chairman of Evonik’s executive board. “We are therefore doing everything possible to supply our partners with the critical lipids they need. At the same time, we are expanding our production capacity and competencies along the entire value chain.”

Lipids are fundamental to produce highly effective mRNA-based vaccines. Only with an increase in lipid supply can the volume of vaccine be further increased. This move marks an expansion of the strategic partnership between Evonik and the vaccine manufacturer BioNTech.

In mRNA-based vaccines, the mRNA is enclosed in a lipid nanoparticle (LNP) that is comprised of specific lipids. The LNP protects the mRNA and delivers it safely into the cell. There it is released so that the vaccine can exert its effect. Evonik has been a contract development and manufacturing organization (CDMO) leader for advanced drug delivery for many decades, supporting pharmaceutical companies worldwide in the development and production of complex parenteral drug products that require formulation technologies such as lipid nanoparticles.

Integrated development partner

The Germany-based company is one of the few integrated development and manufacturing partners for cell and gene therapies, and has been actively involved in various mRNA-based vaccines projects for COVID-19. 

“With our partnership with BioNTech, we are systematically expanding our leading position as an integrated development partner in cell and gene therapies,” says Thomas Riermeier, head of Evonik’s Health Care business line. Evonik’s portfolio includes pharmaceutical excipients such as lipids, as well as CDMO services for the formulation development, GMP manufacturing and aseptic filling of complex parenteral drug products.”

The COVID-19 vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorisation Holder in the European Union, and the holder of emergency use authorizations or equivalent in the United States, United Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries.

The Evonik Health Care business line, which includes products, services and technologies for cell and gene therapies, has been characterized by strong growth and high innovation power for many years. Evonik recognized the potential of gene-based therapeutic approaches early in the emergence of these advances. For example, the specialty chemicals company already develops and formulates lipid nanoparticles in Burnaby, Canada, and operates a facility for the production and fill-finish of commercial quantities in Birmingham, Alabama, USA. “We made a targeted investment in this promising technology in 2016 with the acquisition of Burnaby-based Transferra Nanosciences,” Riermeier explains. The portfolio was further expanded at the beginning of 2020 with the acquisition of Wilshire Technologies, an American manufacturer of non-animal derived excipients for the pharmaceutical industry. This includes PhytoChol, a non-animal derived cholesterol, used in many commercial parenteral pharmaceutical products.



Latest


26 Feb 2021
Melcura HoneyGel revolutionises at-home wound care

Medika SA trading as the Melcura brand, a trusted and well-established wound care brand that has been based in hospitals…

Melcura HoneyGel revolutionises at-home wound care

Medika SA trading as the Melcura brand, a trusted and well-established wound care brand that has been based in hospitals for over 15 years, has finally launched online and at select local pharmacies. Melcura products are a crucial component in one’s arsenal for fast, complete wound healing when an accident…

25 Feb 2021
Environ is named Top Medical Skincare Line of the Decade

Environ Skin Care has won the award for Top Medical Skincare Line of the Decade. With a long list of…

Environ is named Top Medical Skincare Line of the Decade

Environ Skin Care has won the award for Top Medical Skincare Line of the Decade. With a long list of over 100 highly esteemed recognitions received for outstanding products worldwide, South African born, globally recognised professional brand Environ Skin Care has been on an international winning streak the past few…

25 Feb 2021
Adcock Ingram reports resilient trading performance despite COVID-19 challenges

The Adcock Ingram Group has achieved a 4% increase in turnover for the six month period to 31 December 2020.…

Adcock Ingram reports resilient trading performance despite COVID-19 challenges

The Adcock Ingram Group has achieved a 4% increase in turnover for the six month period to 31 December 2020. The company achieved these results despite challenging trading conditions caused by COVID-19, a depressed economy and decline in demand for certain categories of medicine and products. Performance metrics include: •         …

24 Feb 2021
Virtual conference drives the goal to buy Africa for Africa

The Made in Africa Conference and Expo will be the largest ever virtual gathering of and showcase of African buyers…

Virtual conference drives the goal to buy Africa for Africa

The Made in Africa Conference and Expo will be the largest ever virtual gathering of and showcase of African buyers and sellers, taking place on 13 and 14 April 2021.   With the COVID-19 pandemic pushing African nations to develop local solutions to the continent’s challenges, the time has come…


Top stories


25 Jun 2020
How to ensure business agility in a pandemic

BY: Neil Birch, CEO at Novus Holdings Business agility is the capability of a business to respond quickly to a…

How to ensure business agility in a pandemic

BY: Neil Birch, CEO at Novus Holdings Business agility is the capability of a business to respond quickly to a changing environment, whether it be internal or external. Qualities of agile businesses include being adaptive, flexible and creative in your response to change without losing momentum (remaining productive) or vision.…

01 May 2020
Fibertex manufactures critical components for COVID-19 PPE

Fibertex SA, part of the global Fibertex Nonwovens group, has developed versatile high-performance components for protective facemasks and respirators. “Fibertex,…

Fibertex manufactures critical components for COVID-19 PPE

Fibertex SA, part of the global Fibertex Nonwovens group, has developed versatile high-performance components for protective facemasks and respirators. “Fibertex, which continuously invests in technological advancements to meet requirements in diverse industries – has increased production capacity of materials so desperately needed during the global COVID-19 pandemic,” explains Rosa Naidoo,…

23 Apr 2020
Are you South Africa’s best female entrepreneur?

Entries are now open for the Santam Women of the Future Awards 2020 in association with Fairlady and True Love.…

Are you South Africa’s best female entrepreneur?

Entries are now open for the Santam Women of the Future Awards 2020 in association with Fairlady and True Love. Santam, Fairlady and, for the first time this year, Truelove Magazine, have partnered up in the search to find the best female entrepreneurs in the country. Best women entrepreneurs If…

30 Nov 2017
Rooibos could reduce risk of “Type 3” diabetes – a precursor to Alzheimer’s

Researchers at Warren Alpert Medical School at Brown University in the US found a link between a relatively new form…

Rooibos could reduce risk of “Type 3” diabetes – a precursor to Alzheimer’s

Researchers at Warren Alpert Medical School at Brown University in the US found a link between a relatively new form of diabetes, known as “type 3” diabetes and Alzheimer’s disease.


Visit the official COVID-19 government website to stay informed: sacoronavirus.co.za